Adrian Bot

B Adrian

E Wang

Francesco Marincola

MA Cheever

P Romero

P Sharma

Pedro Romero

Journal of Translational Medicine

Crossref

Bot et al. Journal of Translational Medicine 2013, 11:2http://www.translational-medicine.com/content/11/1/2EDITORIAL Open AccessJTM’s Tumor immunology goes broad:announcing the Immunobiology andImmunotherapy sectionAdrian Bot1,2*, Francesco Marincola3,4,5 and Pedro Romero6,7AbstractFor the last four years the Journal of Translational Medicine (JTM) has hosted the Section of Tumor Immunologyand Biological Cancer Therapy. Under the editorial leadership of Dr. Pedro Romero and with the direct support ofthe Society for Immunotherapy of Cancer (SITC), this section enriched the communication between basicimmunological sciences and the clinical investigation arena in oncology. We are re-launching this Section of JTM,now entitled Immunobiology and Immunotherapy, succeeding Tumor Immunology and Biological Cancer Therapy.While aiming to build on the editorial success and focus of its predecessor, this novel Section will have a broaderscope, hosting translational immunology topics pertaining to immunotherapy beyond oncology, includingdisciplines such as inflammation, autoimmunity, transplantation, metabolic disorders and others. As the vision ofthis re-launched Section of JTM broadens up to serve a communication need for translational immunologistsinvolved with immunotherapy irrespectively of the therapeutic area, a novel and focused journal entitled Journal forImmunotherapy of Cancer (JITC) has just been initiated, sponsored by the SITC.During the last four years the JTM’s Section of TumorImmunology and Biological Cancer Therapy, under theeditorial leadership of Dr. Pedro Romero and with thedirect support of the Society for Immunotherapy ofCancer (SITC) [1], has hosted nearly 70 articles – editor-ials, reviews, research articles and others – in accordanceto its mission to enrich the communication between basicimmunological scientists and the clinical investigators inoncology. The vision and objectives of this section co-sponsored by the Society for Immunotherapy of CancerSITC (formerly the International Society for BiologicalTherapy of Cancer or iSBTc), together with BioMedCentral, were articulated in an Editorial by Romero,Fox and collaborators [2]. With that step, JTM be-came a venue for publication of original research arti-cles, literature reviews, opinion/position papers and aforum to discuss the hot issues in tumor immunologyhighly relevant to translating novel immune interventions.* Correspondence: abot@kitepharma.com1Kite Pharma, Inc, 10924 Le Conte Avenue, Los Angeles, CA 90024, USA2Incoming Section Editor of Immunobiology and Immunotherapy of JTM,Bethesda, USAFull list of author information is available at the end of the article© 2013 Bot et al.; licensee BioMed Central LtdCommons Attribution License (http://creativecreproduction in any medium, provided the orThis Section came at a turning point in cancer immuno-therapy, when considerable advances in understanding therelationship between the immune system and cancerstarted to translate to pioneering active immunotherapiessuch as the dendritic cell vaccine ProvengeW and thecheckpoint blocking antibody IpilimumabW now approvedfor clinical use [3,4]. But this was just the start as this sci-entific progress in oncoimmunology fueled unprecedentedinterest and activity in designing and translating novelimmunotherapies, standalone or in context of rationallyselected combinatorial approaches. Paralleling these excit-ing developments in oncoimmunology, a novel journal onits own right, sponsored by SITC, is taking on the missionto provide a venue for the ever growing scientific publica-tion and communication need in this very field. Journalfor Immunotherapy of Cancer (JITC) [5] an open access,peer reviewed journal, will accept various types of submis-sions in basic tumor immunology, clinical and transla-tional cancer immunotherapy, and immune biomarkerswith prognostic or predictive value. In addition, the newjournal will host comments and discussion on timelytopics and innovative concepts. JITC thus aims tocreate a dynamic and global platform for interaction. This is an Open Access article distributed under the terms of the Creativeommons.org/licenses/by/2.0), which permits unrestricted use, distribution, andiginal work is properly cited.Bot et al. Journal of Translational Medicine 2013, 11:2 Page 2 of 2http://www.translational-medicine.com/content/11/1/2and discussion on topics spanning science, policy, strategyand implementation of cancer immunotherapy.We are now also re-launching this section of JTM, tobe entitled Immunobiology and Immunotherapy, suc-ceeding the Tumor Immunology and Biological CancerTherapy section. Through this step, the mission of JTMwill expand with this redesigned section with a muchbroader scope but outside the purview of the SITC. Thisrenewed section will host translational immunologytopics pertaining to immunotherapy beyond oncology,including disciplines such as inflammation, autoimmun-ity, transplantation, metabolic disorders and others. Asimmunology has evolved to be a central discipline con-nected to a wide range of therapeutic areas, the numberand diversity of platform technologies also increased,spanning small molecules, biologics, microbial vectorsand cells. As the vision of this novel section of JTMbroadens up to serve a communication need for transla-tional immunologists involved with immunotherapy irre-spectively of the therapeutic area, a cross fertilizationbetween various fields such as autoimmunity, infectionand cancer, could dramatically catalyze the process ofdiscovery and translation of innovative immunother-apies. To illustrate that principle, it suffices to refer tothe definition of the “immunological constant of tissuerejection” [6], a gene signature that connects immunemediated processes across the board and that couldserve as a rich source of druggable targets and compan-ion biomarkers for novel immune interventions designedto either amplify or quench immune reactions in widelydifferent therapeutic areas. This expansion in the scopeof JTM effected by the introduction of this new sectionof Immunobiology and Immunotherapy mirrors a recentaddition to the journal, namely the section of Patient-Targeted Molecular Therapies [7], that provides a venuefor targeted therapies and translational effectivenesspertaining to diverse therapeutic areas including in-flammation, degenerative disorders, cancer, infection, me-tabolism, neurologic, cardiovascular and genetic diseases,irrespectively of the therapeutic strategy.The Section of Immunobiology and Immunotherapywill host a broad range of submissions in accordancewith JTM’s mission [8]: research articles, commentaries,meeting reports, methodologies, protocols and reviews.On behalf of the JTM we are launching the invitationto submit your work and provide your suggestions forthe Section of Immunobiology and Immunotherapy. Wefirmly believe that our journal’s commitment to providerapid publication, open-access and online communica-tion at global level is key to our vision to become andremain the premier translational medicine journalworldwide. At last but not least, we are very thankful tothe Editorial team of the previous Section of TumorImmunology and Biological Cancer Therapy and we invitethem to continue to support JTM as we are expanding theteam with experts across diverse therapeutic areas.Author details1Kite Pharma, Inc, 10924 Le Conte Avenue, Los Angeles, CA 90024, USA.2Incoming Section Editor of Immunobiology and Immunotherapy of JTM,Bethesda, USA. 3Infectious Disease and Immunogenetics Section (IDIS),Department of Transfusion Medicine, Clinical Center, Bethesda, MD, USA.4Trans-NIH Center for Human Immunology, National Institutes of Health,Bethesda, MD, USA. 5Editor in Chief of JTM, Bethesda, USA. 6Ludwig Centerfor Cancer Research of the University of Lausanne, Avenue Pierre-Decker 4,Lausanne 1011, Switzerland. 7Incoming Editor in Chief of the Journal forImmunotherapy of Cancer, the new BMC journal of the Society forImmunotherapy of Cancer (SITC), Lausanne, Switzerland.Received: 14 December 2012 Accepted: 14 December 2012Published: 4 January 2013References1. Soc Immunother Cancer, http://www.sitcancer.org/.2. Romero P, Fox BA, iSBTc Executive Office: Announcing the tumorimmunology and biological cancer therapy section (edited by iSBTc) ofthe Journal of Translational Medicine. J Transl Med 2009,7:80. doi:10.1186/1479-5876-7-80.3. Cheever MA, Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: thefirst FDA-approved therapeutic cancer vaccine. Clin Cancer Res 2011,17:3520–6.4. Sharma P, Wagner K, Wolchok JD, Allison JP: Novel cancer immunotherapyagents with survival benefit: recent successes and next steps.Nat Rev Cancer 2011, 11:805–12.5. J Immunother Cancer, http://www.immunotherapyofcancer.org/.6. Wang E, Monaco A, Monsurró V, Sabatino M, Pos Z, Uccellini L, Wang J,Worschech A, Stroncek DF, Marincola FM: Antitumor vaccines,immunotherapy and the immunological constant of rejection.IDrugs 2009, 12(5):297–301.7. Adrian B, Francesco C: New section in journal of translational medicine:patient-targeted molecular therapies. J Transl Med 2012,10:92. 15 May 2012.8. J Transl Med, http://www.translational-medicine.com/.doi:10.1186/1479-5876-11-2Cite this article as: Bot et al.: JTM’s Tumor immunology goes broad:announcing the Immunobiology and Immunotherapy section. Journal ofTranslational Medicine 2013 11:2.Submit your next manuscript to BioMed Centraland take full advantage of: • Convenient online submission• Thorough peer review• No space constraints or color ﬁgure charges• Immediate publication on acceptance• Inclusion in PubMed, CAS, Scopus and Google Scholar• Research which is freely available for redistributionSubmit your manuscript at www.biomedcentral.com/submit

JTM’s Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section

https://translational-medicine.biomedcentral.com/track/pdf/10.1186/1479-5876-11-2?site=translational-medicine.biomedcentral.com

JTM’s Tumor immunology goes broad: announcing the Immunobiology and Immunotherapy section

Abstract

Similar works

Full text

Available Versions

Crossref